IDEAYA Biosciences Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello, everyone and welcome back. I'm Charles Zhu, one of the Senior Biotech Analyst here at Guggenheim Securities. Our next fireside chat will be with IDEAYA Biosciences, a clinical stage synthetic lethality platform. Joining us here today is IDEAYA Bio's CEO, Yujiro Hata.
Yujiro, thank you very much for your time today. As always, it is a pleasure hosting you. Before we hop into Q&A, could you perhaps give us a three-minute overview of your company platform and pipeline?
Great. First, thank you to Guggenheim for the invitation again this year. And Charles, thank you for hosting our fireside chat. So IDEAYA was founded just over six years ago with a core focus to build the industry leading synthetic lethality-focused precision medicine oncology company.
Today, we have events two programs into the clinic including IDE397, which we believe is a best-in-class MAT2A inhibitor. I hear the patient selection
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
